1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2020, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.
Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 10, 15, 13, 1, 46, 16 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 8 molecules, respectively.
Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Therapeutics Development
Pulmonary Arterial Hypertension - Therapeutics Assessment
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
Pulmonary Arterial Hypertension - Drug Profiles
Pulmonary Arterial Hypertension - Dormant Projects
Pulmonary Arterial Hypertension - Discontinued Products
Pulmonary Arterial Hypertension - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Pulmonary Arterial Hypertension, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Aadi Bioscience Inc, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Abivax SA, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Acceleron Pharma Inc, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Aerami Therapeutics, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Aerovate Therapeutics Inc, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by AI Therapeutics Inc, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Altavant Sciences Inc, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Alterras Therapeutics GmbH, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Apaxen, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by APEIRON Biologics AG, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Apollo Therapeutics LLC, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics Inc, H2 2020
- Pulmonary Arterial Hypertension - Pipeline by Aqualung Therapeutics Corp, H2 2020
- Pulmonary Arterial Hypertension - Dormant Projects, H2 2020
- Pulmonary Arterial Hypertension - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Pulmonary Arterial Hypertension, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aadi Bioscience Inc
- Abivax SA
- Acceleron Pharma Inc
- Aerami Therapeutics
- Aerogen Ltd
- Aerovate Therapeutics Inc
- AI Therapeutics Inc
- Altavant Sciences Inc
- Alterras Therapeutics GmbH
- Apaxen
- APEIRON Biologics AG
- Apollo Therapeutics LLC
- APT Therapeutics Inc
- Aqualung Therapeutics Corp
- ATXA Therapeutics Ltd
- AVEO Pharmaceuticals Inc
- Bayer AG
- Bial - Portela & Ca SA
- Biogen Inc
- Biozeus Pharmaceutical SA
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- C4X Discovery Holdings Plc
- Camurus AB
- Capricor Therapeutics Inc
- Celsion Corp
- Celtaxsys Inc
- Cereno Scientific AB
- Chiesi Farmaceutici SpA
- Complexa Inc
- Denovo Biopharma LLC
- Eli Lilly and Co
- Excubio Pharmaceuticals Inc
- Galectin Therapeutics Inc
- GenThera Inc
- GEXVal Inc
- Gilead Sciences Inc
- Gmax Biopharm Ltd
- Gossamer Bio Inc
- Hanmi Pharmaceuticals Co Ltd
- Insmed Inc
- Insys Therapeutics Inc
- Interprotein Corp
- INVENT Pharmaceuticals Inc
- Johnson & Johnson
- Keros Therapeutics Inc
- Liquidia Technologies Inc
- LTT Bio-Pharma Co Ltd
- Martin Pharmaceuticals Inc
- Merck & Co Inc
- Mezzion Pharma Co Ltd
- Mifcare
- Morphogen-IX Ltd
- Nadian Bio Ltd
- Nippon Shinyaku Co Ltd
- Nissan Chemical Corp
- Northern Therapeutics Inc
- Novartis AG
- Pfizer Inc
- Pharmosa Biopharm Inc
- PhaseBio Pharmaceuticals Inc
- PHPrecisionMed LLC
- Proteo Inc
- Pulmokine Inc
- Q BioMed Inc
- Radikal Therapeutics Inc
- Recursion Pharmaceuticals Inc
- Relief Therapeutics Holding AG
- Respira Therapeutics Inc
- Resverlogix Corp
- Reviva Pharmaceuticals Inc
- Ribomic Inc
- Shijiazhuang Zhikang Hongren New Drug Development Co Ltd
- Sosei Heptares
- SteadyMed Therapeutics Inc
- Suda Pharmaceuticals Ltd
- Sulfateq BV
- Topadur Pharma AG
- Translate Bio Inc
- Tritech Biopharmaceuticals Co Ltd
- United Therapeutics Corp
- Vascular BioSciences
- Vasculonics LLC
- VasThera Co Ltd
- Velocity Pharmaceutical Development LLC
- Vivus Inc
